The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Cognitive Enhancers as Adjuncts to Psychotherapy: Use of D-Cycloserine in Phobic Individuals to Facilitate Extinctionof Fear
Abstract
BACKGROUND: Traditional pharmacological approaches to treating psychiatric disorders focus on correcting presumed biochemical abnormalities. However, some disorders, particularly the anxiety-related disorders exemplified by specific phobia, have an emotional learning component to them that can be facilitated with psychotherapy. OBJECTIVE: To determine whether D-cycloserine (DCS), a partial agonist at the N-methyl-d-aspartate receptor that has previously been shown to improve extinction of fear in rodents, will also improve extinction of fear in human phobic patients undergoing behavioral exposure therapy. DESIGN: Randomized, double-blind, placebo-controlled trial examining DCS vs placebo treatment in combination with a precisely controlled exposure paradigm. SETTING: Participants were recruited from the general community to a research clinic. PARTICIPANTS: Twenty-eight subjects with acrophobia diagnosed by the Structured Clinical Interview for DSM-IV were enrolled. INTERVENTIONS: After we obtained pretreatment measures of fear, subjects were treated with 2 sessions of behavioral exposure therapy using virtual reality exposure to heights within a virtual glass elevator. Single doses of placebo or DCS were taken prior to each of the 2 sessions of virtual reality exposure therapy. Subjects, therapists, and assessors were blind to the treatment condition. Subjects returned at 1 week and 3 months posttreatment for measures to determine the presence and severity of acrophobia symptoms. MAIN OUTCOME MEASURES: Included were measures of acrophobia within the virtual environment, measures of acrophobia in the real world, and general measures of overall improvement. An objective measure of fear, electrodermal skin fluctuation, was also included during the virtual exposure to heights. Symptoms were assessed by self-report and by independent assessors at approximately 1 week and 3 months posttreatment. RESULTS: Exposure therapy combined with DCS resulted in significantly larger reductions of acrophobia symptoms on all main outcome measures. Subjects receiving DCS had significantly more improvement compared with subjects receiving placebo within the virtual environment (1 week after treatment, P</=.001; 3 months later, P</=.05). Subjects receiving DCS also showed significantly greater decreases in posttreatment skin conductance fluctuations during the virtual exposure (P</=.05). Additionally, subjects receiving DCS had significantly greater improvement compared with subjects receiving placebo on general measures of real-world acrophobia symptoms (acrophobia avoidance [P</=.02], acrophobia anxiety [P</=.01], attitudes toward heights [P</=.04], clinical global improvement [P</=.01], and number of self-exposures to real-world heights [P</=.01]); the improvement was evident early in treatment and was maintained at 3 months. CONCLUSION: These pilot data provide initial support for the use of acute dosing of DCS as an adjunct to exposure-based psychotherapy to accelerate the associative learning processes that contribute to correcting psychopathology.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“DCS is an agonist of the N-methyl-D-aspartate (NMDA) glutamate receptor, and it has been shown to increase the efficacy of exposure therapies for a number of anxiety disorders (Hofmann, Sawyer, and Asnaani, 2012; Ressler, Rothbaum, Tannenbaum, Anderson, et al. 2004).”
From Advancing the treatment of anxiety disorders in transition‐age youth: a review of the therapeutic effects of unconscious exposure. (2025) · cites this paper as Ressler, Rothbaum, Tannenbaum, Anderson, et al. 2004
In the citing paper
“Participants who received the drug (oral administration two to four hours before each session) showed greater improvements than those who received a placebo.”
From Mediators and Mechanisms of Change in Psychotherapy Research (2007) · cites this paper as Ressler et al. 2004
In the citing paper
“The effects were evident one week and three months after treatment.”
From Mediators and Mechanisms of Change in Psychotherapy Research (2007) · cites this paper as Ressler et al. 2004
In the citing paper
“Recently, DCS combined with imaginal or virtual reality exposure (VRE) therapy has been shown to reduce length of treatment for some anxiety disorders, including acrophobia (Ressler et al, 2004), social phobia (Guastella et al, 2008; Hofmann et al, 2006), and panic disorder (Otto et al, 2010), which, like PTSD, include learned avoidance and cued emotional distress as salient symptoms.”
From D-cycloserine augmentation of exposure therapy for post-traumatic stress disorder: a pilot randomized clinical trial (2014) · cites this paper as Ressler et al, 2004
In the citing paper
“The choice of dosing regimen for our studies was based on the Ressler et al (2004) study, which showed that there was no difference in efficacy between the 50 and 500 mg dose of DCS on enhancing exposure therapy outcomes.”
From D-cycloserine augmentation of exposure therapy for post-traumatic stress disorder: a pilot randomized clinical trial (2014) · cites this paper as Ressler et al (2004)
In the citing paper
“We chose weekly dosing, administered 90 min before exposure sessions, as this regimen has been effective in multiple animal and human fear extinction studies (Ledgerwood et al, 2003; Ressler et al, 2004; Walker et al, 2002)”
From D-cycloserine augmentation of exposure therapy for post-traumatic stress disorder: a pilot randomized clinical trial (2014) · cites this paper as Ressler et al, 2004
In the citing paper
“These pilot data add to the literature showing that DCS-enhanced exposure therapy is effective for the treatment of anxiety disorders (Hofmann et al, 2006; Ressler et al, 2004).”
From D-cycloserine augmentation of exposure therapy for post-traumatic stress disorder: a pilot randomized clinical trial (2014) · cites this paper as Ressler et al, 2004
In the citing paper
“Our data, in conjunction with that of Ressler et al (2004), Hofmann et al (2006), and Otto et al (2010), form a compelling pattern of evidence supporting the hypothesis that DCS may facilitate extinction learning.”
From D-cycloserine augmentation of exposure therapy for post-traumatic stress disorder: a pilot randomized clinical trial (2014) · cites this paper as Ressler et al, 2004
In the citing paper
“Shortly thereafter, several groups reported that DCS administration before or after exposure therapy, a form of treatment based on the principles of fear extinction learning, was effective in alleviating the symptoms of acrophobia (67), panic disorder (68), social anxiety disorder (69, 70), and obsessive–compulsive disorder (71–73).”
From Conditioned fear associated phenotypes as robust, translational indices of trauma-, stressor-, and anxiety-related behaviors (2014) · cites this paper as [67]
In the citing paper
“The rationale for selecting 50 mg as the dose was that this dose showed efficacy in previous work examining exposure enhancement with pre-session administration of DCS (10, 11).”
From D-cycloserine enhancement of fear extinction is specific to successful exposure sessions: evidence from the treatment of height phobia (2013) · cites this paper as [10]
In the citing paper
“In humans, DCS administration can likewise facilitate the loss of fear resulting from exposure that causes incomplete fear loss in controls (acrophobia: Ressler, Rothbaum, Tannenbaum, Anderson, Graap, Zimand, Hodges, & Davis, 2004; social phobia: Guastella, Richardson, Lovibond, Rapee, Gaston, Mitchell, & Dadds, 2008; Hofmann, Meuret, Smits, Simon, Pollack, Eisenmenger, Shiekh, & Otto, 2006;”
From D-cycloserine facilitates context-specific fear extinction learning (2008) · cites this paper as Ressler, Rothbaum, Tannenbaum, Anderson, Graap, Zimand, Hodges, & Davis, 2004
In the citing paper
“Indeed, in clinical studies, Ressler et al (2004) and Hofmann et al (2006) have recently reported that DCS facilitates fear extinction in patients with anxiety disorders.”
From Effects of Single Prolonged Stress and D-Cycloserine on Contextual Fear Extinction and Hippocampal NMDA Receptor Expression in a Rat Model of PTSD (2008) · cites this paper as Ressler et al, 2004
In the citing paper
“This, considered collectively with findings from animal studies, leads to the postulation that DCS administration without extinction training cannot facilitate fear extinction.”
From Effects of Single Prolonged Stress and D-Cycloserine on Contextual Fear Extinction and Hippocampal NMDA Receptor Expression in a Rat Model of PTSD (2008) · cites this paper as Ressler et al, 2004
In the citing paper
“Heresco-Levy et al (2002) used daily chronic dosing without exposure therapy, while Hofmann et al (2006) and Ressler et al (2004) used acute dosing with exposure therapy.”
From Effects of Single Prolonged Stress and D-Cycloserine on Contextual Fear Extinction and Hippocampal NMDA Receptor Expression in a Rat Model of PTSD (2008) · cites this paper as Ressler et al (2004)
Citations
Cites
An inventory for measuring depression
BECK, A. T. (1961) · Archives of General Psychiatry · doi:10.1001/archpsyc.1961.01710120031004 · Cited by 38,032
The Structured Clinical Interview for DSM-III-R (SCID): I: History, Rationale, and Description
Spitzer, R. L. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820080032005 · Cited by 4,336
Manual for the state-trait anxiety inventory (form Y) : "self-evaluation questionnaire"
Spielberger, C. D., Gorsuch, R. L., & Lushene, R. E. (1970) · Consulting Psychologists Press eBooks · Cited by 2,352
Genetic enhancement of learning and memory in mice
Tang, Y., Shimizu, E., Dubé, G., Rampon, C., Kerchner, G. A., Zhuo, M., Liu, G., & Tsien, J. Z. (1999) · Nature · doi:10.1038/43432 · Cited by 1,878
Context, ambiguity, and unlearning: sources of relapse after behavioral extinction
Bouton, M. E. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01546-9 · Cited by 1,662
Barlow, D. H., Gorman, J. M., Shear, M. K., & Woods, S. W. (2000) · JAMA · doi:10.1001/jama.283.19.2529 · Cited by 953
Behavioral and Neural Analysis of Extinction
Myers, K. M., & Davis, M. (2002) · Neuron · doi:10.1016/s0896-6273(02)01064-4 · Cited by 918
Self-citationMiserendino, M. J. D., Sananes, C. B., Melia, K. R., & Davis, M. (1990) · Nature · doi:10.1038/345716a0 · Cited by 824
Self-citationWalker, D. L., Ressler, K. J., Lu, K.-T., & Davis, M. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-06-02343.2002 · Cited by 815
Self-citationEffectiveness of computer-generated (virtual reality) graded exposure in the treatment of acrophobia
(1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.4.626 · Cited by 694
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–200 of 1,000
Transcranial magnetic brain stimulation: Therapeutic promises and scientific gaps
Wassermann, E. M., & Zimmermann, T. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.09.003 · Cited by 243
Amygdala BDNF signaling is required for consolidation but not encoding of extinction
Chhatwal, J. P., Rattiner, L. M., Davis, M., & Ressler, K. J. (2006) · Nature Neuroscience · doi:10.1038/nn1718 · Cited by 243
Self-citationLedgerwood, L., Richardson, R., & Cranney, J. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.01.023 · Cited by 249
Petrik, D., Lagace, D. C., & Eisch, A. J. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.09.003 · Cited by 241
Clinical Virtual Reality tools to advance the prevention, assessment, and treatment of PTSD
Rizzo, A. ‘., & Shilling, R. (2017) · European Journal of Psychotraumatology · doi:10.1080/20008198.2017.1414560 · Cited by 241
Neurobiology of fear and specific phobias
Garcia, R. (2017) · Learning & Memory · doi:10.1101/lm.044115.116 · Cited by 239
Role of inhibition in exposure therapy
Craske, M. G., Liao, B., Brown, L., & Vervliet, B. (2012) · Journal of Experimental Psychopathology · doi:10.5127/jep.026511 · Cited by 237
Sartori, S. B., & Singewald, N. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107402 · Cited by 236
Cukor, J., Spitalnick, J. S., Difede, J., Rizzo, A., & ROTHBAUM, B. O. (2009) · Clinical Psychology Review · doi:10.1016/j.cpr.2009.09.001 · Cited by 251
Self-citationThe Role of Glutamate in Anxiety and Related Disorders
Cortese, B. M., & Phan, K. L. (2005) · CNS Spectrums · doi:10.1017/s1092852900010427 · Cited by 231
Virtual reality in the diagnostic and therapy for mental disorders: A systematic review
Wiebe, A., Kannen, K., Selaskowski, B., Mehren, A., Thöne, A.-K., Pramme, L., Blumenthal, N., Li, M., Asché, L., Jonas, S., et al. (2022) · Clinical Psychology Review · doi:10.1016/j.cpr.2022.102213 · Cited by 223
Toward a neurobiology of psychotherapy: basic science and clinical applications
Etkin, A., Pittenger, C., Polan, H. J., & Kandel, E. R. (2005) · The Journal of Neuropsychiatry and Clinical Neurosciences · doi:10.1176/jnp.17.2.145 · Cited by 244
Effect of 7,8-Dihydroxyflavone, a Small-Molecule TrkB Agonist, on Emotional Learning
Andero, R., Heldt, S. A., Ye, K., Liu, X., Armario, A., & Ressler, K. J. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2010.10030326 · Cited by 224
Self-citationZhou, W., & Kalivas, P. W. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.06.008 · Cited by 225
Yamamoto, S., Morinobu, S., Fuchikami, M., Kurata, A., Kozuru, T., & Yamawaki, S. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301605 · Cited by 224
Aberrant learning and memory in addiction
Torregrossa, M. M., Corlett, P. R., & Taylor, J. R. (2011) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2011.02.014 · Cited by 223
Pharmacological Treatment of Obsessive-Compulsive Disorder
Pittenger, C., & Bloch, M. H. (2014) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2014.05.006 · Cited by 222
The Biology of Memory: A Forty-Year Perspective
Kandel, E. R. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.3958-09.2009 · Cited by 222
de Kleine, R. A., Hendriks, G.-J., Kusters, W. J. C., Broekman, T. G., & van Minnen, A. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.02.033 · Cited by 220
Interacting brain systems modulate memory consolidation
McIntyre, C. K., McGaugh, J. L., & Williams, C. L. (2011) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2011.11.001 · Cited by 243
Fear Conditioning in Adolescents With Anxiety Disorders: Results From a Novel Experimental Paradigm
Lau, J. Y. F., Lissek, S. M., Nelson, E. E., Lee, Y. M., Roberson‐Nay, R., Poeth, K., Jenness, J. L., Monique Ernst, D., Grillon, C., & Pine, D. S. (2008) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b01e31815a5f01 · Cited by 215
Glycine transporters as novel therapeutic targets in schizophrenia, alcohol dependence and pain
Harvey, R. J., & Yee, B. K. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3893 · Cited by 213
Difede, J., Cukor, J., Wyka, K., Olden, M., Hoffman, H., Lee, F. S., & Altemus, M. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2013.317 · Cited by 212
Animal Models of Neuropsychiatric Disorders
Fernando, A. B. P., & Robbins, T. W. (2011) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-032210-104454 · Cited by 223
Pamplona, F. A., Prediger, R. D. S., Pandolfo, P., & Takahashi, R. N. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0514-0 · Cited by 211
Overview of Diagnosis and Drug Treatments of Anxiety Disorders
Nutt, D. (2005) · CNS Spectrums · doi:10.1017/s1092852900009901 · Cited by 211
Inhibition of action, thought, and emotion: A selective neurobiological review
Dillon, D. G., & Pizzagalli, D. A. (2007) · Applied and Preventive Psychology · doi:10.1016/j.appsy.2007.09.004 · Cited by 218
Arch, J. J., & Craske, M. G. (2009) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2009.05.001 · Cited by 208
New perspectives in glutamate and anxiety
Riaza Bermudo-Soriano, C., Perez-Rodriguez, M. M., Vaquero-Lorenzo, C., & Baca-Garcia, E. (2012) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.04.010 · Cited by 207
Single prolonged stress disrupts retention of extinguished fear in rats.Preprint
Knox, D., George, S. A., Fitzpatrick, C. J., Rabinak, C. A., Maren, S., & Liberzon, I. (2012) · Learning & memory (Cold Spring Harbor, N.Y.) · doi:10.1101/lm.024356.111 · Cited by 202
Otto, M. W., Smits, J. A. J., & Reese, H. E. (2005) · Clinical Psychology Science and Practice · doi:10.1093/clipsy.bpi009 · Cited by 214
Eaton, W. W., Bienvenu, O. J., & Miloyan, B. (2018) · The Lancet Psychiatry · doi:10.1016/s2215-0366(18)30169-x · Cited by 203
Gloster, A. T., Wittchen, H.-U., Einsle, F., Lang, T., Helbig-Lang, S., Fydrich, T., Fehm, L., Hamm, A. O., Richter, J., Alpers, G. W., et al. (2011) · Journal of Consulting and Clinical Psychology · doi:10.1037/a0023584 · Cited by 203
D-cycloserine does not enhance exposure-response prevention therapy in obsessive-compulsive disorder
Storch, E. A., Merlo, L. J., Bengtson, M., Murphy, T. K., Lewis, M. H., Yang, M. C., Jacob, M. L., Larson, M., Hirsh, A., Fernandez, M., et al. (2007) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e32819f8480 · Cited by 200
Impaired Extinction Retention in Adolescent Rats: Effects of D-Cycloserine
McCallum, J., Kim, J. H., & Richardson, R. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.92 · Cited by 198
Rating data are underrated: Validity of US expectancy in human fear conditioning
Boddez, Y., Baeyens, F., Luyten, L., Vansteenwegen, D., Hermans, D., & Beckers, T. (2012) · Journal of Behavior Therapy and Experimental Psychiatry · doi:10.1016/j.jbtep.2012.08.003 · Cited by 220
Litz, B. T., Salters-Pedneault, K., Steenkamp, M. M., Hermos, J. A., Bryant, R. A., Otto, M. W., & Hofmann, S. G. (2012) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2012.05.006 · Cited by 196
de Jongh, R., Bolt, I. L. L. E., Schermer, M., & Olivier, B. (2008) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2007.12.001 · Cited by 198
Storch, E. A., Murphy, T. K., Goodman, W. K., Geffken, G. R., Lewin, A. B., Henin, A., Micco, J. A., Sprich, S. E., Wilhelm, S., Bengtson, M. A., et al. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.07.015 · Cited by 193
Psychiatric Disorders: Diagnosis to Therapy
Krystal, J. H., & State, M. W. (2014) · Cell · doi:10.1016/j.cell.2014.02.042 · Cited by 197
Virtual Reality-Enhanced Extinction of Phobias and Post-Traumatic Stress
Maples‐Keller, J. L., Yasinski, C. W., Manjin, N., & ROTHBAUM, B. O. (2017) · Neurotherapeutics · doi:10.1007/s13311-017-0534-y · Cited by 190
Self-citationThe role of metaplasticity mechanisms in regulating memory destabilization and reconsolidation
Finnie, P. S. B., & Nader, K. (2012) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2012.03.008 · Cited by 189
Cannabinoids modulate hippocampal memory and plasticity
Abush, H., & Akirav, I. (2010) · Hippocampus · doi:10.1002/hipo.20711 · Cited by 186
Facilitation of fear extinction by D-cycloserine: theoretical and clinical implications
Richardson, R., Ledgerwood, L., & Cranney, J. (2004) · Learning & Memory · doi:10.1101/lm.78204 · Cited by 185
Rizzo, A. “., Difede, J., Rothbaum, B. O., Reger, G., Spitalnick, J., Cukor, J., & Mclay, R. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05755.x · Cited by 185
Self-citationBehavioural pharmacology: 40+ years of progress, with a focus on glutamate receptors and cognition
Robbins, T. W., & Murphy, E. R. (2006) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2006.01.009 · Cited by 184
Pharmacological treatment of anxiety disorders: Current treatments and future directions
Farach, F. J., Pruitt, L. D., Jun, J. J., Jerud, A. B., Zoellner, L. A., & Roy‐Byrne, P. (2012) · Journal of Anxiety Disorders · doi:10.1016/j.janxdis.2012.07.009 · Cited by 202
Pharmacological treatment of PTSD – Established and new approaches
Steckler, T., & Risbrough, V. B. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.06.012 · Cited by 188
McLean, C. P., & Foa, E. B. (2011) · Expert Review of Neurotherapeutics · doi:10.1586/ern.11.94 · Cited by 199
Potential Psychiatric Applications of Metabotropic Glutamate Receptor Agonists and Antagonists
Krystal, J. H., Mathew, S. J., DʼSouza, D. C., Garakani, A., Gunduz-Bruce, H., & Charney, D. S. (2010) · CNS Drugs · doi:10.2165/11533230-000000000-00000 · Cited by 180
Flor, H. (2008) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.8.5.809 · Cited by 184
Pharmacological treatments that facilitate extinction of fear: Relevance to psychotherapy
Davis, M., Myers, K. M., Chhatwal, J., & Ressler, K. J. (2006) · NeuroRX · doi:10.1016/j.nurx.2005.12.008 · Cited by 174
Self-citationVirtual Reality Goes to War: A Brief Review of the Future of Military Behavioral Healthcare
Rizzo, A., Parsons, T. D., Lange, B. S., Kenny, P. G., Buckwalter, J. G., ROTHBAUM, B. O., Difede, J., Frazier, J. R., Newman, B., Williams, J., et al. (2011) · Journal of Clinical Psychology in Medical Settings · doi:10.1007/s10880-011-9247-2 · Cited by 182
Self-citationQuidé, Y., Witteveen, A. B., El‐Hage, W., Veltman, D. J., & Olff, M. (2011) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2011.09.004 · Cited by 180
Varvel, S. A., Wise, L. E., Niyuhire, F., Cravatt, B. F., & Lichtman, A. H. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301224 · Cited by 179
Glutamate Receptors in Extinction and Extinction-Based Therapies for Psychiatric Illness
Myers, K. M., Carlezon, W. A., & Davis, M. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.88 · Cited by 177
Self-citationLearning to forget: manipulating extinction and reconsolidation processes to treat addiction
Torregrossa, M. M., & Taylor, J. R. (2013) · Psychopharmacology · doi:10.1007/s00213-012-2750-9 · Cited by 172
Emerging drugs for the treatment of anxiety
Murrough, J. W., Yaqubi, S., Sayed, S., & Charney, D. S. (2015) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2015.1049996 · Cited by 174
Recent advances in the neurobiology of anxiety disorders: Implications for novel therapeutics
Mathew, S. J., Price, R. B., & Charney, D. S. (2008) · American Journal of Medical Genetics Part C Seminars in Medical Genetics · doi:10.1002/ajmg.c.30172 · Cited by 172
Single dose of l -dopa makes extinction memories context-independent and prevents the return of fear
Haaker, J., Gaburro, S., Sah, A., Gartmann, N., Lonsdorf, T. B., Meier, K., Singewald, N., Pape, H.-C., Morellini, F., & Kalisch, R. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1303061110 · Cited by 166
Neurobiology of anxiety disorders and implications for treatment.
Garakani, A., Mathew, S. J., & Charney, D. S. (2006) · PubMed · Cited by 166
Hsiao, F., Klimidis, S., Minas, H., & Tan, E. (2006) · Journal of Clinical Nursing · doi:10.1111/j.1365-2702.2006.01331.x · Cited by 169
Ross, D. A., Arbuckle, M. R., Travis, M. J., Dwyer, J. B., van Schalkwyk, G. I., & Ressler, K. J. (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2016.3325 · Cited by 171
Self-citationA randomized controlled trial of the effect of D-cycloserine on exposure therapy for spider fear
Guastella, A. J., Dadds, M. R., Lovibond, P. F., Mitchell, P., & Richardson, R. (2007) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2006.05.006 · Cited by 164
Cannabinoid facilitation of fear extinction memory recall in humans
Rabinak, C. A., Angstadt, M., Sripada, C. S., Abelson, J. L., Liberzon, I., Milad, M. R., & Phan, K. L. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.06.063 · Cited by 163
Medications development: Successes and challenges
Vocci, F. J., & Ling, W. W. (2005) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.06.010 · Cited by 161
Next-Generation Treatments for Mental Disorders
Insel, T. R. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004873 · Cited by 164
Milad, M. R., Rosenbaum, B. L., & Simon, N. M. (2014) · Behaviour Research and Therapy · doi:10.1016/j.brat.2014.08.006 · Cited by 175
Cognitive enhancement as a pharmacotherapy target for stimulant addiction
Sofuoglu, M. (2009) · Addiction · doi:10.1111/j.1360-0443.2009.02791.x · Cited by 159
The role of the amygdala in the extinction of conditioned fear.
Barad, M., Gean, P., & Lutz, B. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.05.029 · Cited by 168
Bowers, M. E., Choi, D. C., & Ressler, K. J. (2012) · Physiology & Behavior · doi:10.1016/j.physbeh.2012.03.004 · Cited by 155
Self-citationCan fear extinction be enhanced? A review of pharmacological and behavioral findings
Fitzgerald, P. J., Seemann, J. R., & Maren, S. (2013) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2013.12.007 · Cited by 167
Chapter 33. Neuroscience of Psychotherapy
Vaughan, S., & Ahmed, M. (2022) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375233.gg33 · Cited by 152
Variant BDNF Val66Met Polymorphism Affects Extinction of Conditioned Aversive Memory
Yu, H., Wang, Y., Pattwell, S. S., Jing, D., Liu, T., Zhang, Y., Bath, K. G., Lee, F. S., & Chen, Z.-Y. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.5539-08.2009 · Cited by 153
Peña, D. F., Engineer, N. D., & McIntyre, C. K. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.10.021 · Cited by 147
Virtual reality exposure in anxiety disorders: Impact on psychophysiological reactivity
Diemer, J., Mühlberger, A., Pauli, P., & Zwanzger, P. (2014) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2014.892632 · Cited by 146
Bowers, M. E., & Ressler, K. J. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.06.008 · Cited by 155
Self-citationRabinak, C. A., Angstadt, M., Lyons, M., Mori, S., Milad, M. R., Liberzon, I., & Phan, K. L. (2013) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2013.09.009 · Cited by 148
Effects of multiple exposures to d-cycloserine on extinction of conditioned fear in rats
Parnas, A. S., Weber, M. F., & Richardson, R. (2005) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2005.01.001 · Cited by 146
Boschen, M. J., Neumann, D. L., & Waters, A. M. (2009) · Australian & New Zealand Journal of Psychiatry · doi:10.1080/00048670802607154 · Cited by 145
GOFF, D., CATHER, C., GOTTLIEB, J., EVINS, A., WALSH, J., RAEKE, L., OTTO, M., SCHOENFELD, D., & GREEN, M. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2008.08.012 · Cited by 144
Smits, J. A. J., Rosenfield, D., Otto, M. W., Powers, M. B., Hofmann, S. G., Telch, M. J., Pollack, M. H., & Tart, C. D. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.12.009 · Cited by 142
Translating cognition from animals to humans
Keeler, J. F., & Robbins, T. W. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.12.028 · Cited by 137
Virtual Reality Exposure Therapy for Combat-Related PTSD
Rizzo, A., Reger, G., Gahm, G., Difede, J., & ROTHBAUM, B. O. (2009) · Humana Press eBooks · doi:10.1007/978-1-60327-329-9_18 · Cited by 137
Self-citationA meta-analytic examination of attrition in virtual reality exposure therapy for anxiety disorders
Benbow, A. A., & Anderson, P. L. (2019) · Journal of Anxiety Disorders · doi:10.1016/j.janxdis.2018.06.006 · Cited by 136
Self-citationBentz, D., Michael, T., de Quervain, D. J. ‐., & Wilhelm, F. H. (2009) · Journal of Anxiety Disorders · doi:10.1016/j.janxdis.2009.10.011 · Cited by 136
Frielingsdorf, H., Bath, K. G., Soliman, F., Difede, J., Casey, B. J., & Lee, F. S. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05722.x · Cited by 139
A psychobiological rationale for oxytocin in the treatment of posttraumatic stress disorder
Olff, M., Langeland, W., Witteveen, A., & Denys, D. (2010) · CNS Spectrums · doi:10.1017/s109285290000047x · Cited by 135
Systemic blockade of D2-like dopamine receptors facilitates extinction of conditioned fear in micePreprint
Ponnusamy, R., Nissim, H. A., & Barad, M. (2005) · Learning & Memory · doi:10.1101/lm.96605 · Cited by 135
mGluR7 facilitates extinction of aversive memories and controls amygdala plasticity
Fendt, M., Schmid, S., Thakker, D. R., Jacobson, L. H., Yamamoto, R., Mitsukawa, K., Maier, R., Natt, F., Hüsken, D., Kelly, P. H., et al. (2008) · Molecular Psychiatry · doi:10.1038/sj.mp.4002073 · Cited by 135
Woods, A. M., & Bouton, M. E. (2006) · Behavioral Neuroscience · doi:10.1037/0735-7044.120.5.1159 · Cited by 133
Hofmann, S. G., Ellard, K. K., & Siegle, G. J. (2012) · Cognition and Emotion · doi:10.1080/02699931.2011.579414 · Cited by 132
Enhancing exposure-based therapy from a translational research perspective
Hofmann, S. G. (2007) · Behaviour Research and Therapy · doi:10.1016/j.brat.2007.06.006 · Cited by 138
Behavioral and neurobiological mechanisms of extinction in Pavlovian and instrumental learning
Todd, T. P., Vurbic, D., & Bouton, M. E. (2013) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2013.08.012 · Cited by 147
Millan, E. Z., Marchant, N. J., & McNally, G. P. (2010) · Behavioural Brain Research · doi:10.1016/j.bbr.2010.10.037 · Cited by 136
Exposure therapy in eating disorders revisited
Koskina, A., Campbell, I. C., & Schmidt, U. (2013) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2012.11.010 · Cited by 127
The Use of Virtual Reality in Acrophobia Research and Treatment
Coelho, C. M., Waters, A. M., Hine, T. J., & Wallis, G. (2009) · Journal of Anxiety Disorders · doi:10.1016/j.janxdis.2009.01.014 · Cited by 127
Looking beyond fear: The extinction of other emotions implicated in anxiety disorders
Mason, E. C., & Richardson, R. (2009) · Journal of Anxiety Disorders · doi:10.1016/j.janxdis.2009.08.007 · Cited by 126
Innovative solutions to novel drug development in mental health
Insel, T. R., Voon, V., Nye, J. S., Brown, V. J., Altevogt, B. M., Bullmore, E. T., Goodwin, G. M., Howard, R. J., Kupfer, D. J., Malloch, G., et al. (2013) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2013.03.022 · Cited by 124
Hofmann, S. G., Smits, J. A. J., Rosenfield, D., Simon, N., Otto, M. W., Meuret, A. E., Marques, L., Fang, A., Tart, C., & Pollack, M. H. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.12070974 · Cited by 121
Metadata
- Authors
- Ressler, K. J., Rothbaum, B. O., Tannenbaum, L., Anderson, P., Graap, K., Zimand, E., Hodges, L., & Davis, M.
- Affiliations
- Emory University (US)
- Virtually Better (US)
- University of North Carolina at Charlotte (US)
- Venue
- Archives of General Psychiatry
- Publisher
- American Medical Association (AMA)
- Published
- 2004-11-01
- Volume
- 61
- Issue
- 11
- Pages
- 1136
- ISSN
- 0003-990X (ISSN-L)
- OpenAlex
- W2156900283
- Cited by
- 1,063
- References
- 45
- Citations by year
- 2026: 4 · 2025: 13 · 2024: 14 · 2023: 17 · 2022: 54 · 2021: 20 · 2020: 20 · 2019: 31 · 2018: 35 · 2017: 53 · 2016: 30 · 2015: 52 · 2014: 62 · 2013: 74 · 2012: 79
- FWCI
- 82.58
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Archives of General Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Mental Health (MH-047840, MH069884, K01MH069884)
- Topics
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Life Sciences › Neuroscience › Cognitive Neuroscience › Memory and Neural Mechanisms
- Social Sciences › Psychology › Clinical Psychology › Posttraumatic Stress Disorder Research
- Keywords
- D-cycloserine, acrophobia, specific phobia, NMDA receptor partial agonist, fear extinction, virtual reality exposure therapy, nootropic drugs, adjunctive pharmacotherapy, skin conductance, anxiety disorders, fear learning, avoidance behavior, medication adherence
- MeSH terms
- Adult, Combined Modality Therapy, Cycloserine, Desensitization, Psychologic, Double-Blind Method, Extinction, Psychological, Fear, Female, Humans, Male, Middle Aged, Phobic Disorders, Pilot Projects, Placebos, Psychiatric Status Rating Scales, Receptors, N-Methyl-D-Aspartate, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
